Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma

Launched by CITY OF HOPE MEDICAL CENTER · Jul 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to better predict whether chemotherapy will work for patients with esophageal squamous cell carcinoma, a type of esophageal cancer. The researchers believe that by looking at certain changes in DNA from tissue samples taken before treatment, they can identify which patients are likely to benefit from chemotherapy and which may not respond well. This could help doctors make more informed treatment decisions and improve outcomes for patients.

To participate in this trial, individuals need to have a confirmed diagnosis of esophageal squamous cell carcinoma and must be starting their first round of chemotherapy. They also need to provide written consent to be part of the study. Participants will provide a tissue sample before starting chemotherapy and will be followed for two months after treatment to assess how effective the chemotherapy was. Overall, this trial is focused on improving treatment options for patients with this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who had histologically confirmed esophageal squamous cell carcinoma.
• • 2. Patients who had undergone chemotherapy.
• • 3. Patients receiving initial chemotherapy
• • 4. Written informed consent following full study information is provided to the patient.
• Exclusion Criteria:
• • 1. Patients for whom a preoperative biopsy sample cannot be obtained
• • 2. Patients who cannot assess at 2 months later after chemotherapy.
• • 3. Patients with multiple cancers.